Pregnancy and Autoimmune Disease: Medication Safety and Planning

Imagine being told to stop the very medicine that keeps you functional, right when your body is trying to grow a new life. For decades, this was the standard advice for women with autoimmune diseases like lupus or rheumatoid arthritis. Doctors feared the drugs would harm the baby, so patients were told to go off treatment. The result? Severe disease flares, hospitalizations, and often worse outcomes for both mother and child. But the science has changed dramatically.

Today, we know something crucial: uncontrolled autoimmune disease is far more dangerous to a pregnancy than most medications. In fact, recent guidance confirms that the vast majority of standard treatments can be continued safely. If you are planning a pregnancy while managing an autoimmune condition, understanding which drugs to keep, which to swap, and when to switch them is not just helpful-it is essential for a healthy outcome.

The Shift in Medical Consensus: Why Active Disease Is the Real Risk

For years, the fear of teratogenicity (drugs causing birth defects) drove clinical decisions. However, extensive data collected between 2019 and 2024 has flipped this narrative. The European Alliance of Associations for Rheumatology (EULAR) published updated guidance in February 2025, analyzing over 1,200 clinical studies. Their conclusion was clear: approximately 87% of standard autoimmune treatments are safe during conception, pregnancy, and breastfeeding.

Why does this matter? Because active inflammation poses a direct threat to fetal development. Research shows that uncontrolled systemic lupus erythematosus (SLE) carries a 3 to 5 times higher risk of preeclampsia and nearly three times the risk of preterm birth before 34 weeks compared to well-controlled disease. When patients stop their medication, they aren't just risking joint pain; they are risking placental function and fetal growth.

The American College of Obstetricians and Gynecologists (ACOG) supports this view. Data indicates that 63% of patients who stop tumor necrosis factor (TNF) inhibitors at conception experience a disease flare. In contrast, only 20% of those who continue therapy see a flare. This simple statistic changes everything. It means staying on effective medication is usually the safer bet for both you and your baby.

Preconception Planning: The Critical 6-Month Window

You cannot wait until you miss a period to start thinking about medication safety. Some drugs stay in your system for months, affecting early fetal development before you even know you are pregnant. This is why preconception counseling is non-negotiable.

If you are currently taking medications known to cause birth defects, you need to switch to pregnancy-compatible alternatives at least 3 to 6 months before trying to conceive. Here is what that looks like in practice:

• Methotrexate: This drug requires a minimum washout period of 3 months. It is absolutely contraindicated in pregnancy due to a high risk of major congenital anomalies.
• Mycophenolate Mofetil: This medication needs at least 6 weeks to clear from your system. It carries a significant risk of specific ear and eye defects if exposure occurs during organ formation.
• JAK Inhibitors: Guidelines generally recommend avoiding these entirely during pregnancy due to limited safety data, though some international registries show mixed results. Most experts advise stopping them before conception.

The British Society for Rheumatology (BSR) emphasizes that this transition should happen under the supervision of a rheumatologist and a maternal-fetal medicine specialist. Rushing this process leads to gaps in coverage where your disease can flare, or worse, accidental exposure to harmful drugs during the first trimester.

Medication Safety Profiles: What the Data Says

Not all drugs are created equal when it comes to pregnancy. Some have been studied for decades with tens of thousands of documented pregnancies. Others are newer, with sparse data. Here is how the major categories stack up based on the latest evidence.

Note that biosimilars-such as Amjevita or Hyrimoz, which are copies of adalimumab-maintain identical safety profiles to their reference products. You do not need to worry about switching brands affecting safety, provided they are FDA-approved biosimilars.

Navigating the Third Trimester and Breastfeeding

A common myth persists that all immunosuppressants must be stopped at 32 weeks to prevent infection in the newborn. Dr. Kristina Mahan, an immunology specialist for ACOG, has debunked this. Studies involving over 14,000 infants exposed to TNF inhibitors beyond 32 weeks showed zero evidence of increased infection risk. The neonatal infection rate was identical (7.3%) to unexposed infants (7.1%).

However, timing still matters for certain biologics. Drugs like adalimumab and infliximab cross the placenta more readily later in pregnancy. To avoid suppressing your baby’s immune system unnecessarily after birth, many rheumatologists recommend pausing these injections or infusions after 30 weeks. Certolizumab pegol is different because its molecular structure prevents it from crossing the placenta efficiently. It remains in the mother’s circulation but barely reaches the fetus, making it the top choice for maintaining control through delivery.

What about breastfeeding? Good news here too. Approximately 98.4% of biologics have negligible transfer into breast milk. Adalimumab, for example, is detected in less than 0.13% of maternal serum concentration in breast milk samples. Most experts agree that breastfeeding is safe and encouraged for mothers on these therapies, as the benefits outweigh any theoretical risks.

Building Your Care Team: Who Needs to Be Involved?

Managing an autoimmune disease during pregnancy is not a solo effort, nor should it be managed by one doctor alone. The optimal model involves a multidisciplinary team starting at least six months before you try to conceive.

Your core team should include:

1. Your Rheumatologist: They manage the disease activity and adjust medications. They understand the nuances of drug washout periods and flare risks.
2. A Maternal-Fetal Medicine (MFM) Specialist: These are obstetricians with extra training in high-risk pregnancies. They monitor for complications like preeclampsia or fetal growth restriction, which are more common in autoimmune conditions.
3. A Clinical Pharmacist: Often overlooked, pharmacists can provide detailed data on drug interactions and lactation safety that general practitioners may not have access to.

Data from the Duke University Pregnancy Registry shows that structured preconception visits with this type of coordination reduce high-risk medication use at conception from 38.7% to just 8.2%. Don’t skip this step. The anxiety many women feel-68.3% report significant stress about medication safety-is often reduced when they have a clear, coordinated plan.

Real-World Scenarios: Successes and Pitfalls

Let’s look at two real-world examples that highlight why following current guidelines matters.

Scenario A: The Planned Switch Sarah, 32, has rheumatoid arthritis and takes methotrexate. She plans to get pregnant. Six months prior, she meets with her rheumatologist. They switch her to hydroxychloroquine and certolizumab pegol. By the time she conceives, the methotrexate has cleared her system. Her disease remains quiet throughout pregnancy. She delivers a healthy baby at 39 weeks and continues breastfeeding without issues.

Scenario B: The Unplanned Stop Maria, 28, finds out she is pregnant at 8 weeks. Panicked, she stops her adalimumab immediately without consulting her doctor, fearing harm to the baby. At 20 weeks, she experiences a severe flare requiring high-dose prednisone. This steroid use contributes to gestational diabetes, and she delivers prematurely at 34 weeks. The stress and inflammation caused more harm than the medication ever would have.

These stories are common. Patient surveys reveal that 41.7% of women discontinue necessary treatments without physician consultation. This fear-driven decision-making often leads to worse outcomes. Trust the data, not the anxiety.

Frequently Asked Questions